Five Prime Therapeutics stock debuted with a double digit jump in early Nasdaq trading Wednesday after it raised $62 million in an IPO that priced in the middle of its target range. The South San Francisco company led by CEO Rusty Williams sold 4.8 million shares at $13, compared to original plans to sell 4 million shares at between $12 and $14. The company develops protein therapeutics for cancers and autoimmune diseases.
Help employers find you! Check out all the jobs and post your resume.
